Akari Therapeutics, Plc filed a Form 8-K on October 30, 2026, reporting the voting results from a Special General Meeting held on October 28, 2026, at which shareholders approved an increase in shares available under the company's 2023 equity incentive plan.

Key Highlights

  • Meeting date: The Special General Meeting was held on October 28, 2026.
  • Shares entitled to vote: 186,091,889,533 ordinary shares were eligible to vote at the meeting, according to the filing.
  • Votes in favor: 79,142,490,228 ordinary shares were voted for the resolution.
  • Votes against: 1,314,720,000 ordinary shares were voted against, with 22,005,228 abstentions.
  • Plan increase approved: The resolution authorized an increase of 144,000,000,000 ordinary shares (equivalent to 1,800,000 ADSs) available for grants under the 2023 Plan.
  • New aggregate under the 2023 Plan: The total rises from 19,806,000,000 ordinary shares to 163,806,000,000 ordinary shares (equivalent to 2,047,575 ADSs), plus up to 855,637,300 ordinary shares subject to forfeited or cancelled awards under the 2014 Plan.

Akari Therapeutics Special General Meeting: 2023 Plan Authorization Vote Details

According to the filing, Akari Therapeutics, Plc (NASDAQ:AKTX) held a Special General Meeting on October 28, 2026, at which one ordinary resolution was put to a vote of security holders. The company disclosed that proxies were solicited pursuant to its Proxy Statement filed with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. A quorum was established by the number of ordinary shares present or represented by valid proxy.

The single resolution asked shareholders to authorize an increase in the number of shares available for awards under the company's 2023 Plan by 144,000,000,000 ordinary shares, which the filing describes as "the equivalent of 1,800,000 American Depositary Shares." This would bring the aggregate available under the 2023 Plan from 19,806,000,000 ordinary shares to 163,806,000,000 ordinary shares, or the equivalent of 2,047,575 ADSs. The filing also noted that the authorization includes "such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited or cancelled, or expire unexercised."

The filing reported final voting results in ordinary shares: 79,142,490,228 shares voted for the resolution, 1,314,720,000 voted against, and 22,005,228 abstained. The report was signed by Abizer Gaslightwala, President and Chief Executive Officer, on October 30, 2026.

What Was Disclosed

Akari Therapeutics disclosed the final voting outcome from its October 28, 2026 Special General Meeting, confirming shareholder approval of a resolution to expand share availability under the 2023 equity incentive plan by 144,000,000,000 ordinary shares.